D
Senti Biosciences, Inc. SNTI
$5.00 $0.132.67% NASDAQ
Recommendation
Prev Close
$5.00
Volume
1,813,226
Avg Vol (90D)
57,307
Market Cap
$130.02M
Dividend & Yield
--
52-Week Range
$1.52 - $16.94
P/E (TTM)
--
EPS (TTM)
-$12.75
My Lists My Alerts
Access our Premium Ratings
Get Access
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
Senti Bio's SENTI-202, a First-in-Class Off-the-Shelf Logic Gated Selective CD33 OR FLT3 NOT EMCN CAR NK Cell Therapy, Demonstrates Positive Preliminary Clinical Results in the Treatment of Patients with Relapsed/Refractory AML
4/28/2025 - Globe Newswire
Senti Bio to Host Conference Call and Webcast to Discuss SENTI-202 Clinical Data Being Presented at the American Association for Cancer Research (AACR) Annual Meeting 2025 on Monday, April 28th at 8:30 AM ET
4/24/2025 - Globe Newswire
Senti Bio Participates in a Virtual Investor KOL Connect Segment
4/21/2025 - Globe Newswire
Senti Biosciences, Inc. (NASDAQ:SNTI) Short Interest Update
4/19/2025 - MarketBeat
Senti Biosciences, Inc. (NASDAQ:SNTI) Short Interest Update
4/18/2025 - Ticker Report
Senti Bio (NASDAQ: SNTI) to Participate in a Live Virtual Investor Closing Bell Segment
4/16/2025 - GuruFocus
Senti Bio (NASDAQ: SNTI) to Participate in a Live Virtual Investor Closing Bell Segment SNTI ...
4/16/2025 - GuruFocus
Senti Bio (NASDAQ: SNTI) to Participate in a Live Virtual Investor Closing Bell Segment
4/16/2025 - Globe Newswire
Senti Bio Bolsters Scientific Advisory Board with Appointment of James B. Trager, Ph.D.
4/10/2025 - Globe Newswire
Senti Bio Joins Webull Corporate Connect Service Platform
4/7/2025 - Globe Newswire
Senti Bio to Showcase SENTI-202 Clinical Data and Novel Logic Gated Gene Circuit Mechanism of Action in Oral and Poster Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2025
4/3/2025 - Globe Newswire
Senti Biosciences, Inc. (NASDAQ:SNTI) Short Interest Update
3/30/2025 - Ticker Report
Senti Biosciences Inc Reports Q4 2024 EPS of -$0.67, Revenue Misses Estimate at $0.6 Million
3/20/2025 - GuruFocus
Senti Bio Announces Fourth Quarter and Full Year 2024 Financial Results and Recent Pipeline and Corporate Highlights
3/20/2025 - Globe Newswire
Senti Bio Appoints Feng Hsiung to Board of Directors
3/13/2025 - Globe Newswire
Senti Biosciences appoints Jay Cross as CFO
2/25/2025 - Seeking Alpha - Healthcare
Senti Bio Strengthens Leadership Team with Strategic Hires
2/25/2025 - Globe Newswire
ARMISTICE CAPITAL, LLC Acquires Significant Stake in Senti Biosciences Inc
2/15/2025 - GuruFocus
Nantahala Capital Management, LLC Acquires Significant Stake in Senti Biosciences Inc
2/15/2025 - GuruFocus
Senti Biosciences, Inc. (NASDAQ:SNTI) CEO Sells $15,962.54 in Stock
2/7/2025 - MarketBeat
Senti Biosciences Renews Consulting Agreement with Yvonne Li
2/6/2025 - TipRanks Financial Blog
Senti Biosciences receives additional investment of $10M
1/6/2025 - Seeking Alpha - Healthcare
Senti Bio Announces Additional $11.5 Million of Financing
1/6/2025 - Globe Newswire
How Is The Market Feeling About Senti Biosciences?
1/1/2025 - Benzinga
Income Statement
Total Revenue (TTM)
--
EBITDA (TTM)
-$50.44M
EBIT (TTM)
-$54.28M
Net Income (TTM)
-$52.79M
Balance Sheet
Total Assets (Q)
$97.84M
Total Debt (Q)
$33.64M
Total Liabilities (Q)
$47.09M
Book Value Per Share (Q)
$5.31
Cash Flow
Cash from Operations (TTM)
-$41.40M
Cash from Investing (TTM)
$34.00K
Cash from Financing (TTM)
$53.73M
Net Change in Cash (TTM)
$12.37M
Filings
Filing Date
Thursday, March 20, 2025
Period Date
Tuesday, December 31, 2024
Next Filing
Week of May 5 and 9 (est)
Price History
Loading...
Beta
3.12
7-Day Total Return
30.21%
30-Day Total Return
43.27%
60-Day Total Return
13.12%
90-Day Total Return
-10.23%
Year to Date Total Return
31.23%
1-Year Total Return
72.41%
2-Year Total Return
-50.00%
3-Year Total Return
-94.94%
5-Year Total Return
--
52-week Low
Aug 07, 2024 - $1.52
52-week High
Dec 02, 2024 - $16.94
Valuation
Market Cap
$130.02M - Micro Cap
Enterprise Value
$140.16M
Price/Sales (TTM)
--
Price/Book (Q)
0.94
Dividends and Shares
Shares Outstanding
4.66M
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
www.sentibio.com
Phone Number
650 239 2030
Address
2 Corporate Drive
South San Francisco, CA 94080
Country
United States
Year Founded
2016
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Senti Biosciences, Inc. operates as a clinical-stage biotechnology company that develops next-generation cell and gene therapies engineered with its gene circuit platform technologies for... more
NASDAQ 04/25/2025 4:00PM Eastern Quotes delayed